Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026...
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end...